Anthrax, an infectious disease caused by the bacterium Bacillus anthracis, is often treatable in its early stages. But once ...

University of Pittsburgh researchers discovered that a mix of growth factors can rescue cells from late-stage anthrax damage ...

Polycystic ovary syndrome (PCOS) represents a significant health concern for women of reproductive age, manifesting as a ...

Surprisingly, this process does not rely on reactivating the BRAF-ERK pathway, which is the usual resistance mechanism. Using ...

Anthrax, an infectious disease caused by the bacterium Bacillus anthracis, is often treatable in its early stages. But once ...

to both abemaciclib and the ERK inhibitor LY3214996 qualified for phase II. Nine of 40 evaluable patients exceeded the pharmacokinetic thresholds for phase II. Abemaciclib achieved ...

To fight this, doctors often use drugs called BRAF inhibitors, such as vemurafenib, which can stop the cancer’s growth—at ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions ...

Results provide proof-of-concept that ERK pathway reactivation might be an effective, biologically based therapy to prevent anthrax-induced lethality.

Surprisingly, this process does not rely on reactivating the BRAF-ERK pathway, which is the usual resistance mechanism. Using cutting-edge mass spectrometry-based phosphoproteomics and deep ...

These included MEK1 and MEK2, which control a pathway called ERK involved in cellular division and survival, and MEK3 and MEK6, which regulate the p38 pathway that's involved in stress-induced ...